Navigation Links
MIGENIX Appoints Pieter Dorsman to Board of Directors
Date:4/21/2008

VANCOUVER and SAN DIEGO, April 21 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, has appointed Pieter Dorsman to its Board of Directors. Mr. Dorsman is President and a Director of Redpeaks Management, Inc., a financial consulting firm in Vancouver, which advises companies on finance and investment, corporate development, legal structure and overall business strategies. Prior to founding his consulting firm in 2000, Mr. Dorsman was with UBS, Hong Kong, from 1994-1999, the last three years of which he was Associate Director. Prior to UBS, he was with Barclays Bank PLC from 1990-1993.

Concurrent with the appointment of Mr. Dorsman to the Board, Mr. Colin Mallet announced that he will not stand for re-election to the MIGENIX Board at the next Annual General Meeting in September after over ten years of service.

David Scott, Chairman of MIGENIX stated, "We owe a great deal to Mr. Mallet for his long-standing commitment to our company and thank him immensely for his valuable contribution over the years. We are pleased to add Mr. Dorsman's financial expertise to our group of experienced Board members as we look forward to the potential of completing our transition from a pure development company to a revenue-producing company over the coming years."

About MIGENIX

MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs primarily in the area of infectious diseases. The Company's programs include drug candidates for: the prevention of catheter-related infections (Phase III), the treatment of chronic hepatitis C infections (Phase II and preclinical), the treatment of dermatological diseases (end of Phase II), the treatment of serious gram positive bacterial infections (preclinical) and the treatment of hepatitis B infections (preclinical). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at http://www.migenix.com.

"Jim DeMesa"

James M. DeMesa, M.D.

President & CEO

The Toronto Stock Exchange has not reviewed and does not accept

responsibility for the adequacy or accuracy of this release.

CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666 Ext. 233, aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group, Tel: (212) 825-3210, Theproteam@aol.com


'/>"/>
SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
3. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
8. MIGENIX releases CEO message #22
9. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
11. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... IsoPlexis ... against cancer, autoimmune disease and more through a single-cell precision engineering platform, today ... analysis platform developed in the laboratory of Dr. James Heath at the ...
(Date:3/27/2017)... 2017  Perthera,s Chief Bioinformatics Officer and research faculty ... , Ph.D., will be speaking at the American Medical ... March 27, 2017, she will be speaking on the ... Research and Care" (from 10:30 a.m. – 12:00 p.m. ... be a participant in the "Making Precision Oncology Data ...
(Date:3/27/2017)... , March 27, 2017 DarioHealth Corp. ... mobile health and big data solutions, today announced that ... insurance coverage option for U.S. consumers who want to ... DarioHealth has signed strategic alliance agreements with partners ... insurance coverage benefits, and if approved, will supply and ...
(Date:3/24/2017)... March 24, 2017 Sinovac Biotech Ltd. ("Sinovac" or the ... China , today announced that its board of directors ... of the plan from March 27, 2017 to March 27, 2018. The ... About Sinovac Biotech Ltd. ... Sinovac Biotech Ltd. is a ...
Breaking Biology Technology:
(Date:3/7/2017)... March 7, 2017 Brandwatch , the leading social ... The Prince,s Trust to uncover insights to support its reporting, ... The UK,s leading youth charity will be using Brandwatch ... and get a better understanding of the topics and issues that ... ...
(Date:3/2/2017)... LONDON , March 2, 2017 Summary ... require to better understand Merck KGaA and its partnering ... report: https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals ... into the partnering activity of one of the world,s ... reports are prepared upon purchase to ensure inclusion of ...
(Date:2/28/2017)...   Acuant , a leading provider of data ... to new and core technologies building upon the acquisition ... and desktop Acuant FRM TM facial recognition and ... time manual review of identity documents by accredited professionals. ... and most accurate capture software to streamline workflows by ...
Breaking Biology News(10 mins):